- Home
- MPWR vs BIIB Comparison
MPWR vs BIIB Comparison
Compare MPWR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPWR
- BIIB
- Stock Information
- Founded
- MPWR 1997
- BIIB 1978
- Country
- MPWR United States
- BIIB United States
- Employees
- MPWR N/A
- BIIB N/A
- Industry
- MPWR Semiconductors
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- MPWR Technology
- BIIB Health Care
- Exchange
- MPWR Nasdaq
- BIIB Nasdaq
- Market Cap
- MPWR 29.3B
- BIIB 25.1B
- IPO Year
- MPWR 2004
- BIIB 1991
- Fundamental
- Price
- MPWR $580.81
- BIIB $157.90
- Analyst Decision
- MPWR Strong Buy
- BIIB Buy
- Analyst Count
- MPWR 11
- BIIB 25
- Target Price
- MPWR $840.36
- BIIB $260.48
- AVG Volume (30 Days)
- MPWR 1.4M
- BIIB 1.8M
- Earning Date
- MPWR 10-30-2024
- BIIB 10-30-2024
- Dividend Yield
- MPWR 0.86%
- BIIB N/A
- EPS Growth
- MPWR N/A
- BIIB 10.05
- EPS
- MPWR 8.87
- BIIB 11.06
- Revenue
- MPWR $2,039,447,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- MPWR $23.00
- BIIB N/A
- Revenue Next Year
- MPWR $20.49
- BIIB N/A
- P/E Ratio
- MPWR $65.47
- BIIB $14.27
- Revenue Growth
- MPWR 11.62
- BIIB N/A
- 52 Week Low
- MPWR $538.00
- BIIB $153.62
- 52 Week High
- MPWR $959.64
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- MPWR 25.88
- BIIB 24.44
- Support Level
- MPWR $546.71
- BIIB $153.62
- Resistance Level
- MPWR $593.91
- BIIB $175.86
- Average True Range (ATR)
- MPWR 34.80
- BIIB 4.57
- MACD
- MPWR -9.04
- BIIB -0.83
- Stochastic Oscillator
- MPWR 13.65
- BIIB 16.73
About MPWR Monolithic Power Systems Inc.
Monolithic Power Systems is an analog and mixed-signal chipmaker, specializing in power management solutions. The firm's mission is to reduce total energy consumption in end systems, and it serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.